RxDoctor Payments Data

Mandi Strode, APRN

Family · Marshall, ARNPI 1134517014

Payments from drug & device makers

$517in general payments, 2019–2025

Across 27 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mayne Pharma Commercial LLC$185
  • Xeris Pharmaceuticals, Inc.$44
  • Novo Nordisk$34
  • Johnson & Johnson$34
  • Abbott$32
  • GSK$31
  • plus $158 from 9 others

What the payments were for

  • Food & beverage$517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$517 in reported general payments places this provider in the 55th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$2,753
Medicare patients
62
Services billed
126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$64,649
JardianceEmpagliflozin40$37,417
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$32,427
Wellbutrin XlBupropion Hcl12$24,692
RybelsusSemaglutide23$22,779
JanuviaSitagliptin Phosphate19$17,926
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$12,566
MounjaroTirzepatide11$11,800
Repatha SyringeEvolocumab21$11,694
SymbicortBudesonide/Formoterol Fumarate33$8,258
Potassium Chloride102$8,213
MyrbetriqMirabegron18$8,183
Breo ElliptaFluticasone/Vilanterol21$8,125
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$7,190
Pulmicort FlexhalerBudesonide13$5,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$34$87,42889 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$31$42,91068 claims
Astellas Pharma US IncMyrbetriq$14$8,18318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,103 family providers in Arkansas.

Other family in Marshall

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →